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SUMMARY
TWELVE patients with moderately severe angina pectoris completed a double
blind cross-over comparison of conventional propranolol (40 mg q.i.d.) and Inderal
L.A. (160 mg once daily) with regard to therapeutic effectiveness, blood levels,
compliance and patient acceptability.
Exercise tolerance was assessed using standardised treadmill testing at 1, 2, 4,
8, 12 and 24 hours after the morning dose. The double placebo technique was used.
Patient compliance was excellent for both regimes and no serious side effects
were reported. No significant differences in exercise tolerance or blood levels were
observed between the two treatments at any time.
INTRODUCTION
The therapeutic effectiveness of propranolol in angina pectoris is well docu-
mented (Miller et al, 1975). The plasma half-life is 4-6 hours (Chidsey et al, 1975;
McAinsh et al, 1978) and is usually administered 2-4 times daily. A long acting
formulation (Inderal L.A. ICI) has been developed. Preliminary studies indicate
that in healthy volunteers, Inderal L.A. given once daily produces blood levels
comparable to those obtained by giving conventional propranolol 4 times daily
in the same total dosage (Leahey et al, 1979). We compared conventional
propranolol (40 mg q.i.d.) with once daily Inderal L.A. (160 mg) with regard to
therapeutic effectiveness, blood levels, compliance and patient acceptability.
PATIENT SELECTION
Men aged under 70 years attending the cardiology clinic with angina pectoris
were considered for the study. Those with overt heart fai!ure, airways obstruction,
heart block, unstable angina or evidence of myocardial infarction within six
months were excluded. None was receiving digitalis preparations or anti-hyper-
tensive drugs. Patients taking propranolol 40 mg q.i.d. for at least one month
were tested on a treadmill linked to an Avionics stress monitor by the CM5 lead
system (Sheffield and Roitman, 1976) Thirteen patients who could complete one
but not three full stages of the Bruce protocol were studied. Informed consent
was obtained.
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Each patient completed two weeks run-in followed by two 2-week study
periods. During the run-in, patients continued to take conventional propranolol
(40 mg q.i.d.). Before starting the treatment periods, six treadmill tests were
performed 1, 2, 4, 8, 12 and 24 hours after the morning tablet. Resting heart rate,
ST segment displacement and blood pressure were measured. They then walked
at a constant 2.5 m.p.h. up a 12 per cent gradient. At the onset of pain, heart
rate and ST segment displacement were recorded, blood pressure was measured
and the treadmill stopped.
The patients were allocated randomly for two weeks treatment with pro-
pranolol tablets (40 mg q.i.d.) or Inderal L.A. 160 mg once daily. The treatments
were then crossed over. The double placebo technique was used. Two weeks
supply of one capsule daily (9 am) and one tablet q.i.d. (9 am, 1 pm, 5 pm and
9 pm) respectively was provided. Fifty trinitrin tablets were given, to be used only
to relieve pain. After each treatment period tablet counts were performed. Diary
cards were used to record the number and severity of anginal attacks, the number
of trinitrin tablets consumed, subjective sense of well being and level of activity.
The patients were seen weekly. Following each treatment period standardised
treadmill tests were performed as before. Blood samples were taken following
exercise. Plasma propranolol levels were measured by the fluorometric method
(Shand et at, 1970). An analysis of variance was performed to compare differences
between treatments.
RESULTS
One patient withdrew after the first study week because of epigastric burning
attributed to the capsule, identified subsequently as placebo. Twelve completed
the study. Their mean age was 54 years (range 43-57) and the mean duration of
angina was 60.1 months.
Patient compliance as estimated by tablet count was excellent. Ninety eight
per cent of the propranolol tablets and all of the Inderal L.A. capsules were taken.
The number and severity of anginal attacks were similar in the two treatment
periods. There were no statistically significant differences in patients' trinitrin
consumption, subjective sense of well being or activity level between the two
study periods. The mean observations and standard errors of heart rate, blood
pressure and S.T. segment levels at each test are shown in Table 1 and Table 2.
Mean resting systolic and diastolic blood pressures were significantly lower at
one hour while taking propranolol. Mean heart rate at the onset of pain was
significantly lower at one hour and two hours while taking propranolol. No other
statistically significant differences were observed.
The mean duration of exercise performed at each test for both regimes is
shown in Figure 1 and Tab!e 3. There was a slight improvement in exercise
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FIG. I Duration of exercise before symptoms in patients at various intervals after receiving
propranolol or Inderal LA.
tolerance with both drugs between one and two hours but no significant difference
in exercise ability was observed between the two treatments at any time.
The mean blood levels are shown in Figure 2 and Table 3. There were no
statistically significant differences at any time.
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FIG. 2 Blood levels of propranolol and Inderal LA at intervals after administration.
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Resting Values of heart rate blood pressure and ST segment at various intervals
after propranolol (Prop.) or Inderal L.A. (L.A.)
INTERVAL AFTER ADMINISTRATION
1 hour 2 hours 4 hours 8 hours 12 hours 24 hours
Heart Rate
(per minute)
Prop.
L.A.
Systolic B.P.
(mm Hg)
Prop.
L.A.
Diastolic B.P.
(mm Hg)
Prop.
L.A.
S.T. Segment
Depression (mm)
Prop.
L.A.
57+ 1.7 56± 1.6 60+ 2.0 54± 2.2 58+ 2.5 59+ 1.8
58+ 1.7 55± 2.5 59+ 1.8 55+ 1.8 58+ 2.4 59± 2.1
110+ 3* 109+ 8 112+ 4 114+ 4 124+ 5 116+ 4
122+2* 116±4 111+4 112±4 119+4 121±5
64+ 2.8t 67± 2.7 61± 3.1 69+ 3.4 70± 2.9 68± 2.4
73+ 2.Ot 68+ 3.5 63+ 2.2 70+ 2.1 69+ 2.5 72± 3.1
0.6+ 0.2 0.5+ 0.2 0.5± 0.1 0.6± 0.1 0.5± 0.1 0.6± 0.2
0.5+ 0.2 0.5± 0.2 0.4+ 0.1 0.5+ 0.1 0.5± 0.1 0.6± 0.2
t P<0.01 * P<0.05 Other results not significantly different.
TABLE 2
Values of heart rate blood pressure and ST segment at the onset of pain at
various intervals after propranolol (Prop.) and Inderal L.A. (L.A.)
INTERVAL AFTER ADMINISTRATION
1 hour 2 hours 4 hours 8 hours 12 hours 24 hours
96± 2.9t 92± 2.6* 98± 2.6 94± 2.4 96± 2.8 99± 3.3
100+ 3.1t 94± 2.9* 96± 3.1 93± 2.8 97+ 3.0 96± 3.8
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Heart Rate
(per minute)
Prop.
L.A.Systolic B.P.
(mm Hg)
Prop.
L.A.
Diastolic B.P.
(mm Hg)
Prop.
L.A.
ST Segment
Depression (mm)
Prop.
L.A.
134±4 131+ 5 130+ 5 136±6 132±6 136+ 5
139±5 135±5 137+ 7 136±5 137+ 4 137±4
82± 2.9 85+ 2.5 81+ 3.6 79± 3.1 83± 4.2 86± 3.5
83± 2.3 80± 2.9 81+ 2.4 81+ 2.5 83+ 2.3 85± 3.4
1.3± 0.3 1.2± 0.2 1.3+ 0.2 1.4+ 0.2 1.3± 0.2 1.5± 0.3
1.6+ 0.3 1.2± 0.3 1.3± 0.3 1.4+ 0.3 1.4± 0.3 1.4± 0.3
t P<0.01 * P<0.05 Other results not significantly different.
TABLE 3
Exercise duration and plasma proprawlol concentration at various intervals
after propranolol (Prop.) and Inderal L.A. (L.A.)
INTERVAL AFTER ADMINISTRATION
1 hour 2 hours 4 hours 8 hours 12 hours 24 hours
199± 24 202± 19 165± 19 188± 16 185+ 20 173+ 18
176± 18 204±22 175+ 17 188+20 180±24 197±21
Plasma
Concentration
(ng/ml)
Prop.
L.A.
24.1± 6.5 33.6± 7.4
21.2+ 7.5 27.5± 8.5
33.0± 6.4 37.6± 8.2
32.1+7.1 37.0±7.3
37.9+ 8.5 21.8± 7.2
37.8± 8.6 20.0± 6.7
No significant differences present.
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Exercise
Duration
(seconds)
Prop.
L.A.Side effects were few and mild in both treatments. Apart from the patient who
withdrew while taking the placebo capsule, only one patient had a complaint,
fatigue while taking propranolol.
DISCUSSION AND CONCLUSIONS
This study has shown that in chronic dosage patients with angina achieved
comparable plasma propranolol levels and had comparable exercise tolerance
throughout the 24 hours after a single morning capsule of Inderal L.A. (160 mg)
and after conventional propranolol 40 mg q.i.d. These findings support the kinetic
studies on healthy volunteers (Leahey et al, 1979).
No important differences in blood levels or recorded clinical parameters were
observed.
The excellent compliance on both regimes may be attributable to very close
supervision and the patients' enthusiastic co-operation.
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